VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
DYNDyne Therapeutics, Inc.
$19.80$3.3B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksDYNEarnings History

DYN logoDyne Therapeutics, Inc. (DYN) Earnings History

Net Loss

19 years of earnings data (2007–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$452M
● Net Loss
TTM EPS (Diluted)
$-2.74
Per share, diluted
YoY EPS Growth
-3.0%
Slow
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-55.7%
Return on Assets-47.5%
Record Annual Net Income$264MFY2007
Record Quarterly EPS$12.79Q4 2012
Consecutive Profitable Years0years
Q1 2026
Net Income-$121M
EPS (Diluted)$-0.73
YoY Growth-3.0%Slow
QoQ Growth-7.9%Slow

Loading earnings history...

Dyne Therapeutics, Inc. (DYN) Earnings Overview

As of June 21, 2026, Dyne Therapeutics, Inc. (DYN) reported trailing twelve-month net income of -$452M, reflecting -3.0% year-over-year growth. The company earned $-2.74 per diluted share over the past four quarters.

Looking at the long-term picture, DYN's historical earnings data spans multiple years. The company achieved its highest annual net income of $264M in fiscal 2007.

Dyne Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including SRPT ($65M net income, -32.5% margin), CRSP (-$569M net income, -16569.8% margin), BMRN ($269M net income, 10.8% margin), DYN has comparable earnings metrics. Compare DYN vs SRPT →

DYN Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
DYN logoDYNCurrent
-$452M$-2.74--55.7%-3.0%—
SRPT logoSRPT
$65M$0.53-32.5%-53.5%-404.7%
CRSP logoCRSP
-$569M$-5.92-16569.8%-30.2%-49.1%
BMRN logoBMRN
$269M$1.3610.8%5.9%-18.6%
FOLD logoFOLD
-$27M$-0.09-4.3%-11.6%+51.2%
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
Best in group
Lowest in group

DYN Historical Earnings Data (2007–2025)

19 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$446M-40.6%-$468M$-3.47--
2024-$317M-34.5%-$344M$-3.37--
2023-$236M-40.4%-$242M$-3.95--
2022-$168M-12.6%-$171M$-3.23--
2021-$149M-154.2%-$150M$-2.93--
2020-$59M-333.9%-$59M$-1.24--
2019-$14M-181.4%-$14M$-0.30--
2018-$5M-106.3%-$5M$-0.47--
2017$76M+106.1%-$412M$0.4715.0%-81.4%
2016-$1.24B-2580.0%-$640M$-9.61-90.8%-46.9%
2015$50M+174.6%$64M$0.405.9%7.6%
2014-$67M+81.2%-$318M$-0.53-4.6%-21.7%
2013-$356M-509.2%-$318M$-3.56-11866.7%-10600.0%
2012$87M+105.3%$714M$0.872900.0%23800.0%
2011-$1.65B-603.0%-$236M$-13.48-103.8%-14.9%
2010-$234M+81.5%-$11M$-1.93-10.1%-0.5%
2009-$1.26B-825.3%-$834M$-1.25-51.1%-33.8%
2008$174M-34.1%$709M$0.204.9%20.0%
2007$264M-$605M$0.258.5%19.5%

Download Data

Export DYN earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

19+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DYN — Frequently Asked Questions

Quick answers to the most common questions about buying DYN stock.

What is DYN earnings per share (EPS)?

DYN trailing twelve-month (TTM) diluted EPS is $-2.74, reflecting -3.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2007 to 2025 is available in the table on this page.

What is Dyne Therapeutics, Inc.'s net income?

Dyne Therapeutics, Inc. (DYN) trailing twelve-month net income is $-452M as of 2025. Earnings declined -3.0% year-over-year.

Is DYN profitable?

DYN is not currently profitable on a TTM basis, reporting a net loss of $-452M. Net margin is N/A. Investors should monitor for a return to profitability.

What is DYN's earnings growth rate?

DYN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2007 to 2025.

What are DYN's profit margins?

Dyne Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -55.7%.

Is DYN growing earnings?

DYN earnings growth is slowing. Current YoY EPS growth of -3.0% trails the 5-year CAGR of N/A. TTM net income is $-452M.

What was DYN's best earnings year?

Dyne Therapeutics, Inc.'s highest annual net income on record is $264M, achieved in fiscal year 2007. Earnings history on this page spans 2007 to 2025 and includes all annual and quarterly figures.

What were DYN's earnings last quarter?

DYN's most recent reported quarter was Q1 2026. Net income was $-121M with diluted EPS of $-0.73. For a full breakdown of all quarters, see the quarterly earnings table on this page.

DYN Earnings Over Time (2007–2025)

Net income & EPS — annual and quarterly view